BRIDGEND, WALES – July 18, 2025 – South Wales-based healthcare innovator MPM Health Limited today announced its official rebranding to Molomix Bioscience Ltd. The strategic change reflects the company’s sharpened focus on deploying revolutionary molecular and multi-omic diagnostic technologies across the UK and Europe. The company has also launched its new domain, molomix.co.uk.

The rebrand marks a pivotal moment for the company as it moves to a dedicated B2B service model, providing advanced diagnostic platforms as a complete, subscription-based service. The new name, Molomix Bioscience, was chosen to more accurately represent the company’s core mission: making sophisticated, rapid molecular and multi-omic analysis accessible at the point of need.

This new direction is captured in the company’s powerful new strapline: “Rapid Molecular Multiomics: On-Site, On-Demand, On-Hand.”

“This is more than just a name change; it’s a declaration of our focused strategy,” said Stephen Pickett, CEO of Molomix Bioscience. “Our journey as MPM Health was crucial, but it became clear that our future lies in being a specialised service provider. Molomix Bioscience perfectly captures our expertise in the molecular and multi-omic fields and our commitment to delivering a complete, end-to-end solution for our partners.”

Molomix Bioscience will continue its exclusive UK partnership with global technology pioneer SiGenex to deploy their automated diagnostic platforms. These “Lab-on-a-Chip” systems are designed to drastically cut the time, cost, and risk associated with DNA sequencing and pathogen detection, directly addressing critical needs in clinical and commercial laboratories.

“We are personally committed to fighting cancer and tackling the challenges of other difficult-to-diagnose conditions,” he continued. “By providing these revolutionary platforms without the barrier of capital expenditure, we can empower clinicians, researchers, and scientists with the tools they need to make faster, more informed decisions. Our goal is to level the playing field, particularly in areas facing health inequalities, and to make a tangible impact on patient outcomes.”

The company is currently preparing for a formal comparative study with a leading Welsh University to validate the technology within the Welsh healthcare ecosystem. The first commercial platforms are expected to be available in early 2026, following successful MHRA approvals.

With its new identity, Molomix Bioscience is poised to become a key player in the shift towards a decentralised, on-demand diagnostic landscape, driving innovation from its headquarters in South Wales to partners across Europe.

For more information, please visit the new company website at molomix.co.uk.